Overview


According to FutureWise analysis the market for arthralgia drugs in 2023 is US$ 70.26 billion, and is expected to reach US$ 98.55 billion by 2031 at a CAGR of 4.30%.

Arthralgia, or joint pain, is a common symptom arising from various underlying causes, including arthritis, injury, inflammation, or systemic illnesses. Managing arthralgia often involves the use of pharmaceutical interventions. One of the primary classes of drugs employed in arthralgia treatment is Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). 

These medications, including widely used options like ibuprofen and naproxen, function by inhibiting enzymes responsible for prostaglandin production, thereby reducing pain and inflammation. Acetaminophen, while lacking the anti-inflammatory properties of NSAIDs, is another frequently employed over-the-counter option for mild to moderate joint pain. In cases of more severe arthralgia, particularly associated with autoimmune disorders like rheumatoid arthritis, Disease-Modifying Antirheumatic Drugs (DMARDs) play a pivotal role. DMARDs, such as methotrexate and hydroxychloroquine, modulate the immune system to alleviate inflammation and slow disease progression. For cases refractory to traditional DMARDs, Biologic Response Modifiers or biologics offer a targeted therapeutic approach. Derived from living organisms, biologics specifically target components of the immune system involved in inflammation. While powerful, corticosteroids are employed with caution due to their potential side effects and are generally reserved for short-term relief of severe joint pain.

FutureWise Market Research has published a report that provides an insightful analysis of Arthralgia Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Arthralgia Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Allergan
  • Abbott
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC.
  • Zydus Cadila

(Note: The list of the major players will be updated with the latest market scenario and trends)

As the global population continues to age, the prevalence of arthralgia and related joint disorders is expected to rise. Older individuals are more susceptible to joint pain due to wear and tear on their joints over time, creating a larger patient pool for arthralgia drugs. Arthritis, including osteoarthritis and rheumatoid arthritis, significantly contributes to arthralgia. With an increasing number of people being diagnosed with various forms of arthritis, there is a growing demand for effective arthralgia drugs.  Ongoing research and development in pharmaceuticals have led to the discovering of new and more effective drugs for treating arthralgia. This includes biological therapies and targeted treatments that address the underlying causes of joint pain.  Improved awareness about joint health, along with advances in diagnostic techniques, has led to earlier and more accurate diagnoses of arthralgia and related conditions. This, in turn, drives the demand for appropriate treatment options.
However, some arthralgia drugs, especially those in more potent classes like biologics and corticosteroids, may have significant side effects or potential risks. Balancing efficacy with safety remains a challenge in drug development. Biologic drugs, while highly effective, tend to be expensive compared to traditional therapies. This can limit access for some patients, especially in regions with limited healthcare resources or without comprehensive insurance coverage, hampering the market growth.
 

By Drug Type

  • Non-steroidal anti-inflammatory (NSAID)
  • Corticosteroids
  • Antidepressants
  • Narcotics
  • Anticonvulsants
  • Antibiotics
  • Others

By Dosage Form

  • Injection
  • Tablets
  • Cream
  • Others

By Route of Administration

  • Topical
  • Parenteral
  • Oral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to factors such as a large elderly population, high prevalence of arthritis, well-established healthcare infrastructure, and vigorous R&D activities in the pharmaceutical sector. In addition, increasing adoption of biologic therapies, rising awareness about joint health, and advancements in drug development contribute to the growth of this market in North America.

 

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Arthralgia Drugs Market By Drug Type, By Dosage Form, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Arthralgia Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Arthralgia Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Arthralgia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Arthralgia Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Non-steroidal anti-inflammatory (NSAID)
        2. Corticosteroids
        3. Antidepressants
        4. Narcotics
        5. Anticonvulsants
        6. Antibiotics
        7. Others

  • 8.   Arthralgia Drugs Market, By Dosage Form Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Tablets
        3. Cream
        4. Others

  • 9.   Arthralgia Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Topical
        2. Parenteral
        3. Oral
        4. Others

  • 10.   Arthralgia Drugs Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 11.   Arthralgia Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 12.   North America Arthralgia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Arthralgia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Arthralgia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Arthralgia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GlaxoSmithKline plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Mylan N.V.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Sanofi
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Boehringer Ingelheim International GmbH.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. AstraZeneca
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Johnson & Johnson Private Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Merck & Co., Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. F. Hoffmann-La Roche Ltd.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Bristol-Myers Squibb Company
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Eli Lilly and Company
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Allergan
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Abbott
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. LEO Pharma A/S
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
        17. Sun Pharmaceutical Industries Ltd.
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
          18. Aurobindo Pharma
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Lupin
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
         20. Hikma Pharmaceuticals PLC
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
        21. Amneal Pharmaceuticals LLC.
          21.1. Company Overview
          21.2. Product Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview
         22. Zydus Cadila
          22.1. Company Overview
          22.2. Product Portfolio
          22.3. SWOT Analysis
          22.4. Financial Overview
          22.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients